Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses

EMBO Molecular Medicine(2023)10.15252/emmm.202317580Source: DataRank Database

Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses is a research paper published in EMBO Molecular Medicine (2023). On theSindex it has a DataRank of 0.928. It has been cited 26 times, with 20 citing works in its 1-hop citation network.

N/A

0.928DataRank · unranked

Scored on demand from live citation data

26 citations · 20 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: goldTopics (40)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 53%Citation Network 47%

Base Score Contribution

0.494

From this paper's citation signal

Citation Network Contribution

0.433

From 17 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 20 citers.

Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
Science2024115 citations50 referencesContributes 0.095
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy
Nature Communications202430 citations54 referencesContributes 0.064
Design of SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
bioRxiv (Cold Spring Harbor Laboratory)20235 citations34 referencesContributes 0.053
Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates
Nature Communications202524 citations69 referencesContributes 0.047
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
medRxiv20237 citations54 referencesContributes 0.039

Authors (21)

Pietro Di Lucia ORCID,Micol Ravà ORCID,Davide Marotta ORCID,Elisa Bono ORCID,Stefano Grassi

Live enrichment

PubMed:36946379 PMC:PMC10165354

EC | ERC | HORIZON EUROPE European Research Council

Grant: 725038

Functional Biology of Hepatic CD8+ T cells

EC | ERC | HORIZON EUROPE European Research Council

Grant: 957502

IL-2 gene therapy for chronic hepatitis B virus infection

Fondazione AIRC per la ricerca sul cancro ETS

Grant: 19891

Fondazione AIRC per la ricerca sul cancro ETS

Grant: 22737

Ministero della Salute

Grant: RF‐2018‐12365801

Ministero dell'Università e della Ricerca

Grant: PE00000007,INF‐ACT

NIAID NIH HHS

Grant: P01 AI060699

NIAID NIH HHS

Grant: R01 AI129269

goldLicense: CC BY

publisherhttps://link.springer.com/content/pdf/10.15252/emmm.202317580.pdf

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.15252/emmm.202317580

publisherhttps://link.springer.com/article/10.15252/emmm.202317580/fulltext.html

publisherhttps://www.embopress.org/doi/pdf/10.15252/emmm.202317580

Unpaywallhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/emmm.202317580

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

B-LymphocytesAnimalsMice, Inbred C57BLMiceLactamsNitrilesLeucineProlineAntiviral AgentsAdaptive ImmunityCOVID-19SARS-CoV-2Memory T CellsCOVID-19 Drug Treatment

Keywords

Antiviral treatmentAnimal Modelsadaptive immunitySars-cov-2NirmatrelvirMedicine (General)LactamsProlineQH426-470Antiviral AgentsSARS‐CoV‐2MiceMemory T CellsR5-920LeucineNitrilesGeneticsSARS-CoV-2; Adaptive immunity; Animal models; Antiviral treatment; NirmatrelvirAnimalsB-LymphocytesCOVID-19COVID-19 Drug TreatmentMice, Inbred C57BLReports